BiotechTube
Traws Pharma

Traws Pharma

Newtown, United States· Est.
trawspharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

Traws Pharma is a US-based, clinical-stage biotech advancing two distinct oral antiviral programs: ratutrelvir for COVID-19/Long COVID and tivoxavir marboxil for influenza. The company's strategy targets specific viral enzymes to overcome resistance and aims for convenient, ritonavir-free or single-dose regimens. Led by a seasoned team with deep virology and drug development experience, Traws is navigating the competitive and rapidly evolving antiviral therapeutics market.

Infectious DiseaseRespiratory

Technology Platform

Small molecule antiviral development targeting specific viral enzymes (Main protease, Cap-dependent endonuclease) to overcome resistance and improve dosing convenience.

Funding History

2
Total raised:$65M
Series B$40M
Series A$25M

Opportunities

Large, enduring markets for COVID-19 and influenza treatments, with specific unmet needs for ritonavir-free regimens and convenient single-dose oral antivirals.
The threat of pandemic influenza and concerns over antiviral resistance create a favorable environment for novel mechanisms.
Successful data could lead to lucrative partnerships or buyouts with major pharma.

Risk Factors

High clinical development risk associated with any novel therapeutic.
Intense competition from large pharmaceutical companies with established products and greater resources.
Market uncertainty, particularly for COVID-19 therapeutics.
Dependency on raising additional capital to fund operations and clinical trials.

Competitive Landscape

In COVID-19, Traws faces direct competition from Pfizer's Paxlovid and must demonstrate superior safety/convenience. In influenza, it competes with Roche's Xofluza and generic oseltamivir, aiming to beat Xofluza's one-dose regimen with a broader efficacy profile. Numerous other biotechs are also developing next-generation antivirals in both spaces.

More companies in Small Molecule Drugs →More companies in United States →